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Genetic dissection of the miR-200–Zeb1 axis
reveals its importance in tumor differentiation
and invasion
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The epithelial-to-mesenchymal transition (EMT) is an important mechanism for cancer
progression and metastasis. Numerous in vitro and tumor-proﬁling studies point to the miR-
200–Zeb1 axis as crucial in regulating this process, yet in vivo studies involving its regulation
within a physiological context are lacking. Here, we show that miR-200 ablation in the Rip-
Tag2 insulinoma mouse model induces beta-cell dedifferentiation, initiates an EMT expres-
sion program, and promotes tumor invasion. Strikingly, disrupting the miR-200 sites of the
endogenous Zeb1 locus causes a similar phenotype. Reexpressing members of the miR-200
superfamily in vitro reveals that the miR-200c family and not the co-expressed and closely
related miR-141 family is responsible for regulation of Zeb1 and EMT. Our results thus show
that disrupting the in vivo regulation of Zeb1 by miR-200c is sufﬁcient to drive EMT, thus
highlighting the importance of this axis in tumor progression and invasion and its potential as
a therapeutic target.
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M icroRNAs (miRNAs) have emerged as importantmediators of cellular responses to physiological orpathological stress1–3. miRNA-mediated regulation of
fundamental biological processes, such as proliferation and
apoptosis, can link these regulatory RNAs to cancer-relevant
pathways4. Tumors ubiquitously exhibit dysregulated miRNA
expression patterns, providing useful, albeit correlative, infor-
mation for tumor classiﬁcation and prognosis5. The pathophy-
siological relevance of dysregulated miRNAs and their targets in
tumor specimens is difﬁcult to interpret as their aberrant
expression may be confounded by intra-tumoral heterogeneity,
hampering the ability to establish causal relationships between
miRNA/target levels and cancer phenotypes. This caveat high-
lights the importance of genetic studies and rigorous functional
experiments that directly assess the consequences of miRNA
expression manipulation.
The epithelial-to-mesenchymal transition (EMT) is a complex
biological process in which biochemical changes enable epithelial
cells to adopt a mesenchymal phenotype, resulting in a loss of cell
polarity and increased migratory capacity6–8. This program
operates in embryonic development, wound healing, tissue
regeneration and ﬁbrosis, and all stages of cancer progression, as
well as resistance to cytotoxic therapy9,10. The EMT program has
been well studied in carcinomas, in which it involves distinct
molecular processes including the induction of EMT transcription
factors (EMT-TFs), changes in expression patterns of cell-surface
proteins, cytoskeletal reorganization, degradation of extracellular
matrix, and altered expression of speciﬁc miRNAs11–13. Among
the most extensively studied EMT-TFs are those of the ZEB,
SNAIL and TWIST families, which have pleiotropic functions
that include cell invasion and dissemination, but also inﬂuence
cell fate, cancer-stem-cell plasticity, oncogenic transformation,
therapy resistance, immune evasion, and tumor micro-
environment14–16. Furthermore, extra- and intracellular signal-
ing (i.e. TGF-β, ERK, MAPK, and Smad) regulates the activity of
EMT-TFs13. An additional layer of EMT-TF regulation involves
miRNA networks, which inﬂuence EMT via complex feedback
loops with EMT-TFs and establish functional links with other
signaling pathways17,18.
The miR-200 superfamily of miRNAs (referred to as miR-200)
is reported to play a central role in EMT of many epithelial
cancers18–21. Importantly, aberrant expression of miR-200 has
been associated with initiation and progression of malignant
transformation and metastasis formation20. The miR-200 super-
family has ﬁve members that derive from two chromosomal
locations: miR-200b, -200a and -429 from mouse chromosome 4
(human chromosome 1p36.33) and miR-200c and -141 from
chromosome 6 (human chromosome 12p13.31). Based on their
seed sequence harboring a single-base difference, members of
miR-200 are assigned to two functional families, miR-200a, -141
and miR-200b, -200c, -429 (Fig. 1a)22. The activity of these
miRNA families (here referred to as miR-141 and miR-200c,
respectively) has been linked to the regulation of the EMT-TF
Zeb1 (Tcf8, δEf1), which harbors nine conserved miR-200 sites in
its 3′UTR. Forced overexpression of miR-200 represses Zeb1
expression, supporting the prediction of Zeb1 as a miR-200 target
gene23. In addition, Zeb1 can bind and transcriptionally repress
the promoters of the two miR-200 transcription units, thereby
constituting a double-negative feedback loop that has been
demonstrated in vitro20,24,25.
Although clinical studies show intriguing links between the
miR-200–Zeb1 axis, mesenchymal marker expression, and prog-
nostic and therapeutic outcomes18,20,26–28, these studies provide
correlative results that cannot speak to causality or the roles of the
different allelic and functional miRNA subgroups, or to the
functional role of Zeb1 regulation speciﬁcally, as opposed to
regulation of other miR-200 targets. In this study we therefore
take a genetic approach to study the impact of allelic variation of
the miR-200 family and its target Zeb1 by selectively inactivating
the miR-200 alleles or mutating the miR-200 sites in the endo-
genous Zeb1 3′UTR. Our studies reveal a dose-dependence of
miR-200c and exquisite sensitivity of Zeb1 regulation that criti-
cally impacts tumor differentiation and invasion phenotypes of a
well-established tumor model of pancreatic-islet carcinoma.
Results
miR-200 ablation increases tumor progression in RT2 mice.
Our previous ﬁndings demonstrating that miR-200 is a potent
regulator of beta-cell apoptosis29 motivated us to investigate its
role in neuroendocrine cancer utilizing the Rip-Tag2 (RT2)
insulinoma mouse model30. In this model, beta-cell-speciﬁc
expression of the viral oncogene SV40 T-antigen leads to insuli-
noma formation through inactivation of the p53 and retino-
blastoma (Rb) tumor-suppressor pathways. These tumors
progress through a dependable course characterized by the
development of insulin-secreting beta-cell tumors, leading to a
gradual decrease in blood glucose until symptomatic hypogly-
cemic levels are reached at ~12 to 14 weeks of age30–34. Double
knockout of both mir-200 genomic loci in RT2 beta-cells
(RT2_DKO) led to markedly increased survival and elevated
blood-glucose levels relative to RT2 mice (Fig. 1b, c), despite
increasing tumor burden (Fig. 1d). Interestingly, loss of the mir-
141~200c locus contributed more to this phenotype than the mir-
200a~200b~429 locus, as mir-141~200c-deﬁcient RT2 mice
(RT2_141~200cKO) phenocopied RT2_DKO mice, whereas mice
lacking only miR-200a~200b~429 (RT2_Rip-cre_200aﬂox/ﬂox)
resembled RT2 controls (Fig. 1b–d).
We next sought to investigate morphological and functional
changes induced in mir-200-deﬁcient mice by comparing tumors
collected from RT2 and RT2_DKO mice at an early and a late
time point based on the average survival times of the different
genotypes. The “late stage” timepoint for RT2 mice was chosen as
11 weeks, just prior to reaching fatal hypoglycemic levels, and the
“late stage” timepoint for RT2_DKO mice was chosen as 23 weeks
as this preceded the age at which declining health and/or
hypoglycemia necessitated euthanization (Fig. 1b). An “early
stage” of 11 weeks was also selected for RT2_DKO mice as an
additional timepoint for age-matched comparisons to RT2.
At 11 weeks of age, RT2_DKOmice had a greater proportion of
islets than tumors compared to RT2 controls (Fig. 1d, e),
suggesting a delay in islet hyperplasia and proliferation, which
was reﬂected by decreased EdU incorporation (Supplementary
Figure 1a) and lower Ki67, Mcm-2, and PCNA levels in islets of
6-week-old animals (Supplementary Figure 1b). However, using a
RT2 tumor classiﬁcation system35, we determined that the
existing tumors were more invasive in RT2_DKO than RT2 mice,
with a greater proportion of invasive type 1 and 2 carcinomas
relative to noninvasive insulinomas (Fig. 1f). Furthermore, 30% of
the tumors of early-stage RT2_DKO animals were insulin-
negative (vs. 0% in RT2 mice) (Fig. 1e, g), indicative of beta-
cell dedifferentiation and corroborated by the consistent down-
regulation of beta-cell-identity genes already at 6 weeks of age
(Fig. 1h). Apoptosis was also decreased (Fig. 1i), as previously
observed in a noncancer setting upon mir-200 knockout29. The
decreased proliferation and beta-cell dedifferentiation likely
explains why RT2_DKO mice had higher blood glucose than
RT2 mice starting already at 4 weeks of age (Fig. 1c). Notably,
decreased proliferation, dedifferentiation, and increased resis-
tance to apoptosis are all hallmarks of EMT7,20,36, suggesting that
the EMT program was already initiated at an early stage. At the
late-stage timepoint of 23 weeks RT2_DKO mice had more
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invasive tumors compared to late-stage RT2 mice as well as to
early-stage RT2_DKO mice (Fig. 1f). Tumors of late-stage
RT2_DKO mice were also often insulin-negative (Fig. 1g),
providing an explanation for longer survival despite increased
tumor burden (Fig. 1b–d). Furthermore, they were more resistant
to apoptosis and less proliferative relative to RT2 late-stage
tumors (Fig. 1i; Supplementary Figure 1a), thus retaining
characteristics of EMT that had been initiated early on. Finally,
late-stage RT2_DKO tumors had more instances of vascular
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invasion (Supplementary Figure 1c, d) than late-stage RT2
tumors.
In addition, by end-stage both RT2_141~200cKO and
RT2_DKO mice had macrometastases in the liver, which we
observed at high penetrance in both RT2_141~200cKO and
RT2_DKO mice, but never in RT2 controls (Fig. 1j–l). Interest-
ingly, these metastatic lesions were SV40-positive but insulin-
negative (Supplementary Figure 1e), suggesting that they might
have derived from the poorly differentiated, insulin-negative
tumors speciﬁcally identiﬁed in RT2_DKO mice. These results
show that genetic ablation of both miR-200 clusters in beta-cells
leads to an EMT phenotype, including decreased apoptosis, beta-
cell dedifferentiation, increased local and vascular invasion, and
tumor progression.
miR-200 site mutation in Zeb1 phenocopies mir-200 ablation.
The prevailing model of miRNA function is that they act by
repressing the expression of hundreds of targets, whose additive
effect can impart strong phenotypic consequences1,3. None-
theless, in some cases, deregulation of just a few targets can
explain much of the phenotypic effect observed in genetic models
with loss of miRNA function. This possibility is worthy of con-
sideration for Zeb1, which harbors nine conserved miR-200 sites
in its 3′UTR (Fig. 2a). To explore the contribution of Zeb1
deregulation vs. that of hundreds of other mRNAs with conserved
miR-200 sites37, we generated a knock-in mouse model in which
each of the miR-200 sites in the endogenous Zeb1 locus were
mutated (Zeb1200) to disengage Zeb1 from miR-200 repression
(Fig. 2a; Supplementary Figure 2a, b). To study the contribution
of Zeb1 to the RT2_DKO phenotype, we crossed Zeb1200 into the
RT2 background to generate heterozygous or homozygous mice
(RT2_Zeb1200H or RT2_Zeb1200M, respectively).
Interestingly, RT2_Zeb1200M mice had an increase in survival
resembling that of RT2_DKO mice (Fig. 2b) and exhibited a
comparable reduction in longitudinal blood-glucose levels to
RT2_DKO mice (Fig. 2c), along with increased tumor size
(Fig. 2d). As observed in RT2_DKO animals, early-stage
RT2_Zeb1200M mice had fewer but more invasive tumors
compared to RT2 control mice (Figs. 1e, 2d–f). In addition,
early-stage RT2_Zeb1200M lesions had characteristics indicative of
EMT, including dedifferentiation (Fig. 2e, g, h), resistance to
apoptosis (Fig. 2i), and decreased proliferation (Supplementary
Figure 2c, d). Late-stage RT2_Zeb1200M mice had a greater
proportion of invasive, insulin-negative tumors than late-stage
RT2 or early-stage RT2_Zeb1200M mice (Fig. 2g). Finally,
although tumor burden was similar between RT2_DKO and
RT2_Zeb1200M mice (Supplementary Figure 2g), late-stage
RT2_Zeb1200M tumors metastasized to several distal tissues,
including liver, lymph nodes, and intestine at a penetrance of
almost 100%, even higher than in RT2_DKO mice (Figs. 1l, 2j–l).
Similar to RT2_DKO mice, metastases were also insulin-negative
(Supplementary Figure 2h), suggesting migration of dedifferen-
tiated tumor cells. Together, these data revealed that mutating the
miR-200 sites of a single target gene phenocopied the ablation of
both miR-200 clusters in pancreatic beta-cells, indicating that
Zeb1 is the primary mediator of the dedifferentiation and
invasion phenotype. We also investigated the impact of gene
dosage of Zeb1: strikingly, mice that had only one mutated Zeb1
allele (RT2_Zeb1200H) phenotypically resembled that of
RT2_Zeb1200M and RT2_DKO mice (Fig. 2b–d, k, l), highlighting
the sensitivity of this pathway.
To investigate the broader relevance of the miR-200–Zeb1 axis
in epithelial cancers, we crossed the mutated Zeb1 allele into the
pancreatic ductal adenocarcinoma (PDAC) “KPC” model38. This
mouse model harbors mutations in Kras and Trp53 that are
frequently mutated in human PDAC and is an extensively used
preclinical model of this aggressive cancer39. While survival was
unaffected in KPC Zeb1200H and KPC Zeb1200M mice (Supple-
mentary Figure 2i), they had signiﬁcantly greater end-stage tumor
burden compared to KPC mice (Supplementary Figure 2j). All
mice had tumors that had progressed to the invasive PDAC stage.
Interestingly, however, KPC Zeb1200H and KPC Zeb1200M tumors
were less differentiated than KPC tumors: some were classiﬁed as
“poorly differentiated” as they had solid regions with complete
absence of ducts, but the “moderately differentiated” tumors also
had less deﬁned ducts compared to KPC tumors (Supplementary
Figure 2k, l). Upregulation of Zeb1 thus led to increased
dedifferentiation as observed in the RT2 background. Further-
more, KPC Zeb1200M mice had increased liver micrometastasis,
reﬂected by a greater proportion of CK19-positive cells compared
to KPC mice (Supplementary Figure 2m, n). Collectively, these
data emphasize the importance of the miR-200–Zeb1 axis in the
progression of other epithelial cancers as well.
mir-200KO or Zeb1200 mutation perturbs target network. To
investigate the RT2_DKO and RT2_Zeb1200M phenotypes at the
molecular level, we performed RNA sequencing of islets isolated
from 6-week-old mice, to capture the primary changes in gene
expression leading to the end-stage phenotype. Surprisingly, Zeb1
transcript levels increased by only 30% in RT2_DKO and 55% in
RT2_Zeb1200M islets compared to RT2 controls (Fig. 3a), a
modest increase that was further conﬁrmed at the protein level
(Fig. 3b). Furthermore, comparison of wild-type and mutant Zeb1
allelic expression in RT2_Zeb1200H islets revealed minor but
consistently higher expression of the mutant allele compared to
the WT allele (Fig. 3c). Zeb1 transcript and protein levels were
evaluated in tumors as well, revealing an increase of 50, 37, and
105%, respectively, in protein levels in RT2_DKO, RT2_Zeb1200H
and RT2_Zeb1200M animals compared to RT2 (Fig. 3d; Supple-
mentary Figure 3a, b).
Fig. 1 miR-200 ablation promotes tumor growth, malignancy, and invasion. a Diagram of murine miR-200 superfamily (seed regions boxed). b Percent
survival of RT2 mice with one or both miR-200 genomic clusters ablated (RT2, RT2_Rip-Cre_200aﬂ/ﬂ, RT2_141~200cKO, RT2_DKO, n= 42, 8, 43, 36,
respectively). c Random-fed blood glucose (RT2, RT2_Rip-Cre_200aﬂ/ﬂ, RT2_141~200cKO, RT2_DKO, n= 11, 7, 11, 13, respectively). Dotted line represents
onset of severe hypoglycemia. d Tumor burden in different age classes (box, 25th and 75th percentiles; central line, median; left to right: n= 9, 5, 4, 6, 9, 7,
11, 14 mice). e Representative insulin/glucagon and SV40 immunoﬂuorescence staining of whole pancreas (left; insulin-negative tumors outlined; scale bar
= 2mm) and zoomed-in regions (right; all tumors outlined; scale bar= 100 μm). LN lymph node. f Percent tumors per grade (n= 5 mice per group; RT2,
early-stage RT2_DKO, late-stage RT2_DKO, n= 55, 9, 31 tumors respectively). g Percent insulin-positive and -negative tumors (n= 5 mice per group; RT2,
early-stage RT2_DKO, late-stage RT2_DKO, n= 67, 6, 31 tumors, respectively). h Mean log2FC (with 95% conﬁdence intervals) of beta-cell-identity genes
in RT2_DKO vs. RT2 islets of 6-week-old mice. i Percent of TUNEL-positive nuclei (n= 2 mice per group; RT2, early-stage RT2_DKO, late-stage RT2_DKO,
n= 17, 15, 17 lesions per group). j Representative H&E staining and SV40 immunoﬂuorescence staining of late-stage RT2_DKO liver (scale bar= 2mm).
k Representative images of late-stage RT2 and RT2_DKO mice. l Percent mice with macrometastasis in difference age classes. Data in c, i are plotted as
mean ± SD. Signiﬁcance was evaluated by bMantel Cox test, c two-tailed t test with Holm−Sidak correction (vs. RT2), d, i one-way ANOVA with Dunnett’s
multiple comparisons test (vs. RT2) and h empirical Bayes method. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07130-z
4 NATURE COMMUNICATIONS |          (2018) 9:4671 | DOI: 10.1038/s41467-018-07130-z | www.nature.com/naturecommunications
We next explored whether this modest magnitude of Zeb1
derepression was sufﬁcient to affect Zeb1 transcriptional net-
works downstream. Expression of potential Zeb1 target genes
(from Zeb1 ChIP)40 was signiﬁcantly downregulated in both
RT2_DKO and RT2_Zeb1200M islets relative to RT2 controls
(Fig. 3e, f). Interestingly, Zeb1 target genes were signiﬁcantly
further downregulated in RT2_Zeb1200M mice compared to
RT2_DKO mice (Supplementary Figure 3c). Heat-map analysis
also shows that Zeb1 target genes were highly differentially
expressed in RT2_Zeb1200M vs. RT2 islets and more similar in
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expression to RT2_DKO islets (Fig. 3g). These results support the
conclusion that it is indeed Zeb1 and its target genes that mediate
the common phenotype observed in RT2_DKO and
RT2_Zeb1200M mice, and that stronger regulation of Zeb1 in
RT2_Zeb1200M mice compared to RT2_DKO might contribute to
the more extreme metastatic phenotype (Figs. 1l, 2l).
ZEB1 and miR-200 expression inversely correlates in numerous
cancer cell lines41–43. This expression pattern is due not only to
miR-200-mediated regulation of ZEB1 but also direct repression
of both mir-200 clusters by ZEB1, establishing a double-negative
feedback loop, which is thought to contribute to plasticity
between the epithelial and mesenchymal states20,24,25. Measure-
ments of miR-200 levels in RT2_Zeb1200M islets revealed an 85
−90% decrease of members of the miR-200a~200b~429 cluster
and a 94% decrease in those of the miR-141~200c cluster relative
to RT2, with no difference in expression levels in RT2_Zeb1200M
mice compared to RT2_DKO animals (Supplementary Fig-
ure 3d, e). This resulted in signiﬁcant upregulation of predicted
targets of the miR-200c family in RT2_DKO and RT2_Zeb1200M
islets (Fig. 3h, i), but surprisingly little increase in expression of
miR-141 predicted targets (Supplementary Figure 3f, g). Of note,
compared to ChIP targets of other random transcription factors,
Zeb1 ChIP targets were not particularly enriched in predicted
miR-200 targets (Supplementary Figure 3h), implying that in
RT2_Zeb1200M islets, miR-200c targets were regulated by miR-
200c rather than directly by Zeb1.
To compensate for the loss of miR-200 in Zeb1-mutant mice,
we crossed in a transgenic allele in which the expression of MiR-
141~200c is controlled by the rat insulin promoter (Rip) and is
thus independent of Zeb1 regulation (RipmiR-141~200c)29,
thereby enabling stable expression of miR-141~200c despite
elevated Zeb1 expression (Supplementary Figure 3d, i).
RT2_Zeb1200M_RipmiR-141~200c mice had reduced survival
and blood glucose levels compared to RT2_Zeb1200M and
RT2_Zeb1200H mice, presumably attributable to regulation of
miR-200 targets other than Zeb1. Notably, survival and long-
itudinal blood glucose levels of RT2_Zeb1200H_RipmiR-141~200c
mice were shifted towards RT2 controls even further than the
RT2_Zeb1200M_RipmiR-141~200c mice, indicating that the pre-
sence of one wild-type Zeb1 allele was sufﬁcient to partially rescue
the phenotype in the presence of adequate levels of miR-
141~200c (Fig. 3j, k). This partial rescue thus further highlighted
the signiﬁcance of tuning Zeb1 expression in the process of
dedifferentiation and invasion of islet-cell carcinomas. Further-
more, while the expression of the RipmiR-141~200c allele neither
reduced the invasiveness of primary tumors (Fig. 3l) nor inhibited
downregulation of Cdh1 (Supplementary Figure 3j), these tumors
were more frequently insulin-positive than RT2_Zeb1200M tumors
(Fig. 3m), thus explaining the shortened survival and lower blood
glucose upon miR-141/200c re-expression. In addition, while
metastases in RT2_DKO, RT2_Zeb1200H, and RT2_Zeb1200M mice
were insulin-negative, RT2_Zeb1200H_RipmiR-141~200c and
RT2_Zeb1200M_RipmiR-141~200c mice had insulin-positive
metastases (Fig. 3n, o; Supplementary Figures 1e, 2h). Taken
together, these data suggest that while direct Zeb1 targets are
responsible for the invasive phenotype, Zeb1’s inﬂuence on
dedifferentiation is mediated at least in part via its down-
regulation of miR-200.
Finally, we sought to determine the relative importance of Zeb1
vs. other miR-200 targets in tumor progression. As predicted
miR-141 targets were not signiﬁcantly regulated in our model
(Supplementary Figure 3f, g), we selected the most upregulated
miR-200c predicted targets in RT2_DKO vs. RT2 and in
RT2_Zeb1200M vs. RT2 islets (of which 80.2% were overlapping)
and performed an siRNA screen in an RT2_DKO tumor-derived
cell line. As EMT is a well-described mechanism of metastasis
development44 and thought to be regulated by miR-200 based on
multiple in vitro and correlative studies18,45, we speciﬁcally
sought to understand the relative role of these predicted targets in
repressing the epithelial phenotype in RT2_DKO and
RT2_Zeb1200M tumors by measuring mRNAs of epithelial
markers, E-Cadherin (Cdh1), Epithelial Cell Adhesion Marker
(Epcam), and Occludin (Ocln) upon siRNA knockdown. Knock-
down of Zeb1 was by far the most efﬁcient at inducing both Cdh1
(Supplementary Figure 3k) and Epcam (Supplementary Figure 3l),
and among the most efﬁcient at inducing Ocln (Supplementary
Figure 3m), supporting the hypothesis that the phenotype in
RT2_DKO mice was predominantly mediated through ZEB1 and
its downstream regulation of EMT.
miR-200 regulation of Zeb1 engages the EMT program in vivo.
We next sought to determine whether we could detect broader
EMT transcriptional changes in RT2_DKO and RT2_Zeb1200
islets at the pretumor stage. Interestingly, Ingenuity pathway
analysis of differentially expressed genes revealed enrichment in
functions including cellular movement, organismal development,
cell-to-cell signaling and interaction, and cell morphology, which
are key aspects of the EMT process (Supplementary Figure 4a).
Further analysis was performed utilizing a list of core EMT genes
generated from a meta-analysis of 18 independent studies46.
Principal coordinate analysis revealed a gradient of clusters that
grouped according to genotype and phenotype, with the
RT2_DKO mice exhibiting the less severe metastatic phenotype,
located between the RT2 control mice and the more extreme
RT2_Zeb1200M mice (Fig. 4a). The EMT process involves complex
gene-expression changes; EMT genes can be subdivided into
genes that are downregulated, i.e. associated with the epithelial
phenotype (eEMT), or upregulated, i.e. associated with the
Fig. 2 Mutation of miR-200 sites in Zeb1 is sufﬁcient to phenocopy miR-200 ablation. a Murine Zeb1 3′UTR, miR-200 site conservation, and mutated miR-
200 site sequences. b Percent survival of RT2 mice with Zeb1 mutation (RT2, RT2_Zeb1200H, RT2_Zeb1200M, n= 42, 45, 26, respectively). c Random-fed
blood glucose (RT2, RT2_Zeb1200H, RT2_Zeb1200M, n= 11, 11, 10, respectively). Dotted line represents onset of severe hypoglycemia. d Tumor burden in
different age classes (box, 25th and 75th percentiles; central line, median; from left to right: n= 9, 4, 4, 4, 5, 11, 12 mice). e Representative insulin/glucagon
and SV40 immunoﬂuorescence staining of whole pancreas (left; insulin-negative tumors outlined; scale bar= 2 mm) and zoomed-in regions (right; all
tumors outlined; scale bar= 100 μm). LN lymph node. f Percent tumors per grade (n= 5 mice per group; RT2, early-stage RT2_Zeb1200M, late-stage
RT2_Zeb1200M, n= 55, 17, 16 tumors, respectively). g Percent insulin-positive and -negative tumors (n= 5 mice per group; RT2, early-stage RT2_Zeb1200M,
late-stage RT2_Zeb1200M, n= 67, 12, 15 tumors, respectively). h Mean log2FC (with 95% conﬁdence intervals) of beta-cell-identity genes in RT2_Zeb1200M
vs. RT2 islets of 6-week-old mice. i Percent TUNEL-positive nuclei (n= 2 mice per group; RT2, early-stage RT2_Zeb1200M, late-stage RT2_Zeb1200M, n= 17,
21, 13 lesions, respectively). j Representative H&E and SV40 immunoﬂuorescence staining of late-stage RT2_Zeb1200M liver (scale bar= 2mm).
k Representative images of late-stage RT2_Zeb1200H and RT2_Zeb1200M mice. l Percent of mice with macrometastasis in difference age classes. c, i Data are
plotted as mean ± SD. Signiﬁcance was evaluated by bMantel Cox test, c two-tailed t test with Holm−Sidak correction (vs. RT2), d, i one-way ANOVA with
Dunnett’s multiple comparisons (vs. RT2) and h empirical Bayes method. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001
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mesenchymal phenotype (mEMT). eEMT and mEMT mRNA
levels were signiﬁcantly regulated in both RT2_DKO and
RT2_Zeb1200M animals, with greater fold-change regulation in
RT2_Zeb1200H and RT2_Zeb1200M islets in general (Fig. 4b),
consistent with greater regulation of Zeb1 and its targets in these
animals. Speciﬁcally, classic mEMT markers such as Vim, Twist1
and Snai1 were consistently increased in all three metastatic
models, and levels of eEMT markers Ocln, Epcam, and Cdh1 were
strongly reduced (Supplementary Figure 4b). Furthermore, Cdh1
protein, whose loss is a key contributor to EMT, tumor
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malignancy, and progression47,48, was also substantially down-
regulated in islets and tumors (Figs. 3b, 4c, d; Supplementary
Figure 3a, b). Of note, analysis of liver metastases in both
RT2_DKO and RT2_Zeb1200M mice revealed no re-expression of
Cdh1, suggesting that in this model, mesenchymal-to-epithelial
transition (MET) is unlikely to be required for metastatic growth
(Supplementary Figure 4c). Finally, the stem-cell markers Sox2,
Tcf4, and c-myc were upregulated in RT2_Zeb1200M islets, in line
with the acquisition of stemness properties, which has been
associated with EMT49,50 (Supplementary Figure 4b).
Zeb1 and EMT are regulated by miR-200c but not by miR-141.
To distinguish the speciﬁc roles of the miR-200c and miR-141
families, we infected RT2_DKO tumor-derived cells with adeno-
viruses harboring either the endogenous Mir141~200c locus (ad-
141~200c) or the Mir141 or Mir200c genes alone (ad-141 and ad-
200c, respectively) (Supplementary Figure 5a, b). Overexpression
of miR-200c led to a dosage-dependent repression of Zeb1 tran-
scripts and strong induction of Cdh1 mRNA, which was not
observed upon miR-141 overexpression (Fig. 5a, b). Similar reg-
ulation was also evident at the protein level, with a response to
miR-141 expression observed only at MOI 500, a titer at which
some cell toxicity was noted (Fig. 5c). In contrast, forced over-
expression of miR-200c in a RT2_Zeb1200M cell line did not
change Zeb1 or Cdh1 levels (Supplementary Figure 5c–g). In
addition, Zeb1 3′UTR luciferase assays in the Min6 beta-cell line,
which endogenously expresses both miR-141 and miR-200c,
revealed that mutations of miR-141 sites alone did not cause
derepression compared to the WT 3′UTR, whereas 3′UTRs
harboring mutations in only miR-200c sites or in both miR-141
and miR-200c sites were derepressed similarly (Fig. 5d). More-
over, miR-141 overexpression had no effect on the reporter
harboring the WT 3′UTR, whereas overexpression of miR-200c
or miR-141~200c led to decreased reporter activity (Fig. 5d).
These results demonstrate that members of the miR-200c family,
but not of the miR-141 family, function as major regulators of
Zeb1 and its downstream network.
To delineate the roles of the miR-141 and miR-200c families at
regulating EMT more broadly, we performed RNA sequencing of
RT2-DKO-derived cells infected with adenovirus to achieve miR-
141 and miR-200c expression levels similar to endogenous levels
in RT2 islets (Supplementary Figures 3e, 6a). We conﬁrmed that
predicted miR-200 targets were only regulated upon expression of
their respective seed family (Supplementary Figure 6b).
Hierarchical clustering analysis revealed that ad-141~200c- and
ad-200c-infected cells clustered together, whereas ad-141-infected
cells were more similar to ad-Ctrl-infected cells (Fig. 5e).
Ingenuity analysis identiﬁed cellular movement as the most
regulated functional category upon miR-141~200c or miR-200c
expression (Supplementary Figure 6c), consistent with a major
role in EMT regulation. Similar analysis for ad-141-infected cells
revealed no enrichment in any functional annotation, due to the
small number of signiﬁcantly regulated genes. Although eEMT
genes were signiﬁcantly upregulated in ad-141-infected cells (P=
2.52e−03), the fold-change was much greater in ad-200c- and ad-
141~200c-infected cells (P= 6.52e−41 and P= 4.99e−45, respec-
tively), with only a small additional increase in fold-change of ad-
141~200c- compared to ad-200c-infected cells. Similarly, mEMT
genes were not signiﬁcantly downregulated upon miR-141
expression, but were reduced upon overexpression of miR-200c
(P= 2.78e−02) and miR-141~200c (P= 8.49e−03) (P values
calculated by hypergeometric test) (Fig. 5f). Collectively, these
results indicate that miR-200c, but not miR-141, profoundly
inhibits the process of EMT, with the strongest effect of miR-200c
treatment being derepression of eEMT genes.
Mechanistically, this effect was indirect, as miR-200c predicted
targets signiﬁcantly overlapped with mEMT genes (P= 7.6e−03)
but not with eEMT transcripts (P= 2.3e−01) (Fig. 5f; Supple-
mentary Figure 6d), suggesting that miR-200c acts by repressing
mEMT genes, which in turn upregulates eEMT genes. Indeed, the
most strongly repressed mEMT gene was Zeb1 (Fig. 5f), with
signiﬁcant overlap between Zeb1 ChIP targets and eEMT
transcripts (P= 2e−10) (P values calculated by hypergeometric
test) (Fig. 5g, Supplementary Figure 6e). These results suggest that
it is primarily miR-200c, and not miR-141, that represses
mesenchymal genes including Zeb1, thereby enabling mainte-
nance of epithelial markers such as Cdh1 that are crucial for
preventing EMT-induced tumor progression.
Discussion
The miR-200–Zeb1 axis has been extensively studied in cancer
and implicated in tumor progression through expression analysis
of clinical specimens18,20,26–28. Although most correlation studies
associate loss of miR-200 with increased tumor progression18,
gain of miR-200 has also been associated with disease progres-
sion51–53, thus emphasizing the need for genetic studies to better
understand miR-200 mechanisms in various tumor contexts.
Reduction and overexpression of miR-200 in vitro can be
Fig. 3 Effect of miR-200KO and Zeb1200 mutations on Zeb1 and downstream target regulation. a Mean log2FC (with 95% conﬁdence intervals) of Cdh1 and
Zeb1 in islets. b Immunoblots evaluating ZEB1 and CDH1 in islets (n= 2 mice per lane). Quantiﬁcation is normalized to β-actin and relative to RT2. c Allelic
expression of mutant Zeb1 allele in three RT2_Zeb1200H mice. d ZEB1 quantiﬁcation in end-stage tumors (immunoblots in Supplementary Figure 3b) (n= 10
−13 tumors), normalized to β-actin and calibrator. e, f Cumulative distributions of log2FC of Zeb1 targets in islets of e RT2_DKO vs. RT2 and f RT2_Zeb1200M
vs. RT2. g Hierarchical clustering and heat-map analysis of Zeb1 targets in islets (scale bar represents Euclidian distance between samples). h, i Cumulative
distributions of log2FC of miR-200c predicted targets subdivided by context+ score in islets of h RT2_DKO vs. RT2 and i RT2_Zeb1200M vs. RT2 mice.
P values shown are for context+ <–0.3. j Percent survival of RT2 mice with WT or mutant Zeb1 3′UTR and endogenous or overexpressed miR-200 levels
(RT2, RT2_RipmiR-141~200c, RT2_Zeb1200H_RipmiR-141~200c, RT2_Zeb1200M_RipmiR-141~200c, RT2_Zeb1200H, RT2_Zeb1200M, n= 42, 8, 13, 8, 45, 26,
respectively). k Blood glucose (RT2, RT2_RipmiR-141~200c, RT2_Zeb1200H_RipmiR-141~200c, RT2_Zeb1200M_RipmiR-141~200c, RT2_Zeb1200H, RT2_Zeb1200M,
n= 11, 8, 9, 9, 11, 10, respectively). Dotted line represents onset of severe hypoglycemia. l Percent tumors per grade (RT2, RT2_Zeb1200M, RT2_Zeb1200H_
RipmiR-141~200c, RT2_Zeb1200M_RipmiR-141~200c, from n= 5, 5, 8, 5 mice and n= 55, 16, 24, 15 tumors, respectively). m Percent insulin-positive and
-negative tumors (RT2, RT2_Zeb1200M, RT2_Zeb1200H_RipmiR-141~200c, RT2_Zeb1200M_RipmiR-141~200c, from n= 5, 5, 8, 5 mice and n= 67, 15, 24, 15
tumors, respectively). n Percent animals with insulin-positive and -negative metastases (RT2_Zeb1200H, RT2_Zeb1200M, RT2_Zeb1200H_RipmiR-141~200c,
RT2_Zeb1200M_RipmiR-141~200c, n= 7, 9, 8, 5, respectively). o Representative insulin and SV40 immunoﬂuorescence of RT2_Zeb1200M_RipmiR-141~200c
liver metastases (scale bar= 50 μm). a, c, e–i RNA sequencing of islets of 6-week-old mice (RT2, RT2_DKO, RT2_Zeb1200H, RT2_Zeb1200M, n= 2, 5, 3, 4,
respectively). d, k Data are plotted as mean ± SD. Signiﬁcance was evaluated by a empirical Bayes method, d one-way ANOVA with Dunnett’s multiple
comparisons (vs. RT2), e, f, h, i competitive gene set test, jMantel Cox test, and k two-tailed t test with Holm−Sidak correction (vs. RT2). *P≤ 0.05; **P≤
0.01; ***P≤ 0.001; ****P≤ 0.0001
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sufﬁcient to induce or reverse EMT, respectively, and Zeb1 is
postulated to be important in this process41. Independent
manipulation of Zeb1 expression strongly affects EMT in vitro54,
and a recent study demonstrated that in vivo ablation of Zeb1 in
PDAC led to decreased tumor progression and metastasis16.
Although these studies indicate that the miR-200–Zeb1 axis is
important in EMT, they do not address whether in vivo regula-
tion of Zeb1 to the extent achieved by miR-200 is sufﬁcient to
have phenotypic consequence. This question can be addressed by
mutating the miR-200 sites in the Zeb1 3′UTR, which we show
here in two epithelial cancer models to be sufﬁcient to induce
EMT and have strong effects on tumor dedifferentiation, pro-
gression, and invasion.
Previous work in the RT2 insulinoma model has revealed that
tumor progression occurs with distinct mRNA and miRNA
expression proﬁles at each stage34,55. Interestingly, it was
observed that miR-200 levels were decreased and Zeb1 expression
increased in advanced stage tumors, suggesting that RT2 tumors
endogenously regulate the miR-200–Zeb1 axis55. In addition,
sustained Cdh1 expression was shown to be important in pre-
venting the transition from adenoma to carcinoma56, further
emphasizing the role of EMT in tumor progression in the RT2
model. The presence of rare low-insulin, “met-like primary”
tumors in the RT2 model has also been reported34, reminiscent of
the dedifferentiated invasive tumors that we identiﬁed in
RT2_DKO and RT2_Zeb1200M mice. While the authors suggest
that these tumors may derive either from differentiated tumors or
directly from islet progenitor cells, gene-expression data in
RT2_DKO and RT2_Zeb1200M mice suggest an EMT-associated
dedifferentiation program, as expression of mature β-cell markers
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is reduced while β-cell progenitor markers are not consistently
expressed.
In this study, we selected the RT2 beta-cell tumor model
because previous work in beta cells had demonstrated that miR-
200c is a potent regulator of antiapoptotic genes and that miR-
200c knockout is thus protective against apoptosis29. Our data
reveal a decrease in apoptosis in RT2_DKO and RT2_Zeb1200M
islets and tumors relative to RT2, suggesting a similar role for
miR-200 in beta-cell tumors29. Furthermore, our results thus
suggest that modest derepression of Zeb1 is sufﬁcient to increase
resistance to apoptosis, a common feature in EMT6,50. This
function might be a direct effect of Zeb1 on its targets, or an
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indirect effect through its downregulation of miR-200 through
the miR-200–Zeb1 double-negative feedback loop.
miR-200 and Zeb1 are involved in a double-negative feedback
loop that is thought to stabilize either the epithelial or
mesenchymal state, as well as permit a high degree of plasticity
between the two states20,24,25. Our data demonstrate the in vivo
impact of this loop. Expression analysis of the miR-200 family
showed that all ﬁve miRNAs were downregulated by ~90% in
RT2_Zeb1200M islets, similar to the degree of regulation pre-
viously reported in vitro25. This downregulation had molecular
consequences, reﬂected by strong enrichment in miR-200c target
regulation, and phenotypic consequences, as re-expression of
miR-141~200c in RT2_Zeb1200M mice reduced their survival and
accelerated hypoglycemia. This demonstrates that part of Zeb1’s
mechanism of action is through its regulation of miR-200 and its
targets, and that these miR-200c targets play a particularly strong
role in dedifferentiation. It should be emphasized, however, that
in our analyses, Zeb1 targets identiﬁed by ChIP signiﬁcantly
overlapped with EMT genes and were strongly regulated, indi-
cating that Zeb1 also acts in an miRNA-independent manner, as
exempliﬁed by its direct regulation of Cdh1 and Epcam.
To our surprise, RT2_Zeb1200M mice exhibited a stronger and
more penetrant phenotype than RT2_DKO animals, with tumors
that were more invasive and more frequently insulin-negative, and
a higher penetrance of macrometastasis. Although seemingly
counterintuitive, the observation that miR-200 regulation of a
single target gene had a stronger effect than knockout of the entire
miR-200 family could be due to differential regulation of other
miRNA targets that might be protective against tumor progres-
sion, as the negative feedback loop in RT2_Zeb1200M tumors did
not completely ablate miR-200 levels. Another possibility relates
not to the primary tumor but to metastatic growth: perhaps some
plasticity of miR-200 regulation is required for efﬁcient seeding
and metastasis development, which would have been precluded in
the tumor cells of the miR-200-null RT2_DKO model.
The miR-200 superfamily is often studied as a single family,
but is expressed from two independent polycistronic genomic loci
harboring two separate families, which complicates the functional
analysis of the different families. Our results demonstrate greater
importance for the Mir141~200c cluster in regulating dediffer-
entiation and invasion of RT2 tumors than the
Mir200a~200b~429 cluster. This could be attributable to the
lower expression of the latter cluster in islets29, which may be
tissue-dependent. Our results also show that the miR-200c family
was more potent in regulating Zeb1 and EMT than the miR-141
family. This we observed not only in vitro, consistent with results
of several other studies24,41, but also in vivo, as the EMT tran-
scriptional changes that occurred in RT2_DKO and
RT2_Zeb1200M islets were accompanied by a response of
miR-200c but not miR-141 predicted targets. Interestingly,
absolute quantiﬁcation of miR-200c and miR-141 revealed 2.5-
fold lower expression of miR-141 in islets, although whether this
was an accurate measurement of miRNA levels is unclear due to a
potential bias against miRNAs with low GC content during Trizol
extraction57. To ensure that the lack of Zeb1 response was not
simply due to insufﬁcient miR-141 levels, we performed luciferase
assays and found no response of the Zeb1 3′UTR upon miR-141
site mutation and miR-141 overexpression. In agreement with
our ﬁndings, in a xenograft model, miR-141-overexpressing
tumor cells have a greater capacity to colonize lungs than miR-
200c-overexpressing cells58.
The EMT program is regulated by a complex network of
transcription factors including the SNAIL, TWIST, and ZEB
families, whose expression and importance in EMT is tissue-
dependent13,16. In our system, Zeb1 upregulation was sufﬁcient to
initiate and drive the EMT program. Key EMT-TFs Zeb2, Snai1,
and Twist1 were upregulated as well, but Twist1 was lowly
expressed and unlikely to play a major role. In development and
cancer, Snai1 expression typically precedes and helps induce the
expression of other EMT TFs including Zeb159–61, and thus it is
interesting that in our system Zeb1 can induce Snai1, perhaps
through indirect mechanisms. Although Cdh2 was not increased
in RT2_DKO and RT2_Zeb1200M islets, Vim, a marker for end-
stage EMT62, was strongly upregulated in RT2_DKO and
RT2_Zeb1200M islets. Furthermore, the strong induction of stem-
cell marker Sox2 along with induction of Tcf4, c-myc, and Lgr5
was in line with the dedifferentiation and acquisition of stemness
properties associated with EMT and regulated by Zeb149,50.
Importantly, these molecular signatures of EMT were already
detected in islets of 6-week-old mice, before tumor development,
suggesting that they were all driven by miR-200 loss and Zeb1
overexpression and not by secondary mutations.
An important conclusion of this study is that only subtle
changes in Zeb1 expression, to the degree conferred by dosage-
dependent miR-200c regulation, are sufﬁcient to induce a strong
effect on EMT and cancer progression in two tumor-susceptible
genetic backgrounds, the RT2 and KPC models. This is further
highlighted by the observation that miR-200c-mediated repres-
sion of a single wild-type allele in RT2_Zeb1200H_RipmiR-
141~200c mice is sufﬁcient to partially rescue the phenotype
relative to RT2_Zeb1200M_RipmiR-141~200c mice. In this regard,
it would be interesting to investigate the regulation of miR-200,
Zeb1 and their targets in the progression of human insulinomas
to metastatic, nonfunctional pancreatic neuroendocrine tumors
(PanNET). Given the importance of the miR-200–Zeb1 axis in
many human cancers20,49,51, this suggests the potential ther-
apeutic utility of enhancing miR-200c or repressing Zeb1 in
primary tumors. This is especially compelling because even small
Fig. 5 Zeb1 and EMT programs are regulated by miR-200c but not by miR-141. a, b Relative Zeb1 (a) and Cdh1 (b) expression in RT2-DKO-derived cells
infected with recombinant adenoviruses expressing miR-141, -200c, or both at the indicated MOIs (n= 3 replicates). Expression was measured by qPCR and
normalized to Ad-Ctrl at the corresponding MOI. c Immunoblots depicting ZEB1 and CDH1 expression in lysates of RT2_DKO-derived cells infected with the
indicated adenoviruses at the speciﬁed MOIs. Band densities were quantiﬁed and normalized to tubulin and to appropriate ad-Ctrl (right-hand graphs). d
Normalized luciferase assays (n= 6 replicates) for WT Zeb1 3′UTR, Zeb1200 3′UTR, and Zeb1 3′UTRs harboring mutations either in miR-141 or miR-200c
sites, performed in Min6 cells with endogenous or adenoviral overexpression of miR-200 (MOI 50). e Hierarchical clustering and heat-map analysis of the
top 500 genes with the highest biological coefﬁcient of variation in RT2_DKO cells infected with ad-141~200c, ad-141, or ad-200c relative to ad-Ctrl-infected
cells. The scale bar indicates the Euclidian distance between samples. f Box-and-whisker plots (box, 25th and 75th percentiles; central line, median) of
log2FC of mEMT and eEMT genes in RT2_DKO cells infected with ad-141~200c, ad-141, or ad-200c relative to ad-Ctrl-infected cells. g Overlap between Zeb1
ChIP targets and EMT genes. Colored are the results for EMT genes that are also Zeb1 ChIP targets. e−g RNA sequencing of adenovirus-infected RT2_DKO
cells (n= 2 technical replicates for each adenoviral infection). a–d Data are plotted as mean ± SD. Signiﬁcance was evaluated by b multiple two-tailed t tests
(vs. respective Ad-Ctrl) with Holm−Sidak correction, d two-way ANOVA with Tukey’s multiple comparisons test (vs. respective Zeb1 3′UTR WT and vs.
Ad-Ctrl/ WT Zeb1 3′UTR as indicated), and f competitive gene set test. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001
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reductions of Zeb1 levels could have considerable impact in
preventing EMT and curtailing metastasis, which in turn could
have a profound impact in reducing cancer progression and
mortality. Finally, manipulation of the miR-200–Zeb1 axis could
also be relevant in noncancer settings: beta-cell dedifferentiation
has been shown to be a hallmark beta-cell defect in type 2 dia-
betes; therefore, reversing this process could be a novel ther-
apeutic strategy63–66. It would thus be important to study the
miR-200–Zeb1 axis in nontumor sensitized diabetic models. A
further application could be to improve differentiation of beta-
cells derived from ES cells or to counter the dedifferentiation of
transplanted islets and their in vitro culture, all major hurdles for
beta-cell transplantation therapy67–69.
Methods
Experimental animals. Mice were housed in a pathogen-free animal facility at the
Institute of Molecular Health Sciences at the ETH Zurich. The animals were
maintained in a temperature-controlled room (22 °C), with humidity at 55% and
on a 12 h light−dark cycle (lights on from 0600 to 1800 hours). Mice were fed a
standard laboratory chow and water ad libitum, and the age of mice is indicated in
the ﬁgures and text. All ethical regulations were complied with and all animal
experiments were approved by the Kantonale Veterinäramt Zürich. Animals in the
RT2 background were in a C57BL/6 background. The generation of mice deﬁcient
for Mir141~200c and Mir200a~200b~429 was described previously29. Rip-Cre mice
were kindly provided by P. Herrera and Rip-Tag2 mice were provided by
D. Hanahan. The generation and breeding schemes of Rip-Tag2 mice have been
published30; end-stage was determined as the time point at which random-fed
blood glucose remained below 2.0 mmol/L for 3 consecutive days or dipped below
1.0 mmol/L on any single day, or in the case of RT2_DKO or RT2_Zeb1200M mice
whose blood glucose never went below 2.0 mmol/L, based upon general termina-
tion criteria including rufﬂed fur, hunched posture, and loss of the escape reﬂex.
The LSL-KrasG12D/+; LSL-Trp53R172H; LSL-Trp53R17H/+ (KPC) mouse model of
pancreatic adenocarcinoma was in a mixed 129/Sv BALB/C C57BL/6 background,
and all experiments involved littermate controls; end-stage was determined as the
timepoint at which mice lost 10% of their body weight.
Generation of Zeb1200 mutant mice. To generate the targeting construct, a DNA
fragment containing the mouse Zeb1 locus was subcloned from bacterial artiﬁcial
chromosome (BAC RP23-78D21). The targeting arms spanned exon 8 of Zeb1
including its entire 3′UTR. All nine miR-200 sites were mutated by site-directed
mutagenesis. A LoxP-ﬂanked puromycin-resistance gene was used for positive
selection and diphtheria toxin gene was used for negative selection. Thirty-three
positive clones were obtained from 246 colonies of which two were injected into
C57BL/6j blastocysts and transferred into pseudo-pregnant females. Chimeras were
bred with C57BL/6j mice to generate heterozygous progeny and germline trans-
mission of the mutated allele was veriﬁed by PCR. The puromycin-resistance
cassette was excised by intercrossing with transgenic Cre deleter mice. The phe-
notype of RT2_Zeb1200H and RT2_Zeb1200M mice was conﬁrmed in mouse lines
derived from the two independent ES cell clones.
Blood-glucose measurements. Blood glucose was measured using a Contour
glucometer (Bayer).
Cell line generation from RT2_DKO and RT2_Zeb1200M tumors. To generate
tumor-derived cell lines, tumors were isolated from RT2_DKO and RT2_Zeb1200M
mice, minced, and digested for 18 min in Liberase TM (Roche) at 37 °C, then plated
in Primaria (Corning) plates. Media were changed daily to remove dead cells and
debris, and cells were passaged after 5–7 days and replated. Experiments were
conducted with cells at ~P20.
Immunohistochemistry, lesion staging, and image analysis. Pancreata and
livers were ﬁxed in 4% paraformaldehyde, embedded in parafﬁn, and cut into
3.5 μm sections. Antigen retrieval was performed with 10 mM sodium citrate buffer
(pH 6.0). Sections were permeabilized and blocked in phosphate buffered saline
(PBS) containing 0.1% Triton-X-100, 1% bovine serum albumin (BSA) and 5%
donkey or goat serum. Primary antibody binding was performed overnight at 4 °C,
while secondary antibody incubation was carried out at room temperature for 1 h.
Tissue samples were stained with hematoxylin and eosin (H&E) according to
routine laboratory procedures. Slides were scanned using a ×20 objective on the
Pannoramic 250 Slide scanner (3D Histech) or a ×40 objective on the Aperio AT2
Slide scanner (Leica Biosystems). For experiments in the RT2 background, mice
were tail-vein injected with 10 mg/g body weight of EdU (ThermoFisher) and
sacriﬁced 2 h later. EdU incorporation in islets and tumors was analyzed using the
Click-iT EdU Alexa Fluor 647 HCS Assay (Invitrogen) kit, and the ratio of EdU-
positive nuclei to total nuclei was analyzed for each lesion using QuPath70. Simi-
larly, TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining was
performed using the ApopTag Red In Situ Apoptosis Detection Kit (Merck) and
the ratio of TUNEL-positive to total nuclei was also quantiﬁed for each lesion using
QuPath. For islet and tumor staging, all lesions were analyzed blindly by a Board-
certiﬁed pathologist in one representative H&E section of ﬁve mice per age and
genotype and classiﬁed according to the guidelines provided in Lopez and Hana-
han35. Vascular and lymphatic invasions were deﬁned as the presence of SV40-
positive cells within a CD31-expressing vessel, and total instances were counted in
ﬁve representative sections per age and genotype. For analysis of the KPC model,
degree of metastasis was determined by calculating the percentage of CK19-positive
area over the total DAPI-surface area using NIH ImageJ software (https://imagej.
nih.gov/ij/). KPC tumors were graded according to the recommendations pre-
sented in the consensus report by Hruban et al.71
Tumor burden and macrometastasis penetrance. Tumors were microdissected
from pancreata of mice at various ages and measured in three dimensions. Indi-
vidual tumor volume was approximated using the formula length × width2 × 0.52,
and total tumor burden was calculated as the sum of volumes of all tumors in one
mouse pancreas. Macrometastatic penetrance was determined based on the pre-
sence of metastases visible without the use of a microscope on the liver or on the
intestine.
Immunoblotting. Small tumors, pieces of tumors, or pooled islets (2 mice per lane)
were disrupted in RIPA buffer (150 nM NaCl, 1% Triton-X, 50 mM Tris, 0.5%
sodium deoxycholate, 0.1% SDS), supplemented with Complete, ethylenediami-
netetraacetic acid (EDTA)-free Protease inhibitors (Roche) and Halt Phosphatase
inhibitors (Pierce) using the TissueLyser (Qiagen), followed by sonication. Cells
were washed in PBS, then collected in RIPA buffer and sonicated directly. Protein
concentrations were measured by bicinchoninic acid assay. Laemmli buffer was
added to samples, equal protein amounts were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), transferred by electro-
blotting and membranes blocked in 5% milk/Tris buffered saline with Tween 20
(TBS-T) for 1 h. Membranes were incubated with appropriate antibodies overnight
at 4 °C, then exposed to secondary antibodies for 1 h at room temperature and
developed using ECL Western Blotting Substrate. Band density was evaluated using
MultiGauge (Fujiﬁlm) and normalized to beta actin or tubulin levels. For blots
intended to be compared to each other, data were additionally normalized to a
calibrator sample that was equally loaded on each blot. Uncropped western blots
can be found in Supplementary Figures 7–10.
Antibodies. The following antibodies were used in immunoblotting: anti-E-
cadherin (Cell Signaling, 3195, 1:1000), anti-Zeb1 (Santa Cruz, sc-25388, 1:1000),
anti-Beta-Actin (Cell Signaling, 4970S, 1:1000), and anti-Gamma-Tubulin (Sigma,
T6557, 1:5000). The following antibodies were used for immunohistochemistry:
anti-SV40 T Ag (Santa Cruz, sc-20800, 1:50), anti-Insulin (DAKO, A056401,
1:1000), anti-CD31 (R&D Systems, AF3628, 1:15), anti-Lyve1 (Abcam, ab14917,
1:100), anti-E-cadherin (Abcam, ab76055, 1:200), anti-Glucagon (Millipore,
AB932, 1:200), anti-SMA (Abcam, ab5694, 1:100), anti-CK19 (Abcam, ab52625,
1:400).
Recombinant adenoviruses. Recombinant adenovirus-expressing pre-mir-
141~200c was previously generated29. In brief, 450 bp- and 250 bp-spanning
sequences of pre-miR-141~200c were cloned into pcDNA3 and pAd5 for adeno-
virus production (Viraquest). Adenoviruses expressing miR-141 or miR-200c were
generated by PCR ampliﬁcation of pre-mir-141 or pre-mir-200c with ~200 bp
ﬂanking regions from mouse gDNA using primers listed in the Supplementary
Table 1. Fragments were cloned downstream of a CMV promoter in pVQAd CMV
K-NpA for recombinant adenovirus production (ViraQuest). All adenoviruses
expressed GFP from an independent promoter. Ad-Ctrl was based on the same
vector backbone (including GFP) but lacked the miRNA transgenes. Cell experi-
ments with RT2-DKO- or RT2-Zeb1200M-tumor-derived cell lines were performed
in a 24-well (qPCR) or 6-well format (Immunoblotting), by infecting cells 12 h
post-seeding, and harvesting 48 h later. Data were normalized to the Ad-Ctrl-
treated samples with the equivalent MOI. For the sequencing experiment,
RT2_DKO cells were infected at MOI 100 and harvested 48 h later.
Luciferase assays. The WT Zeb1 3′UTR was PCR-ampliﬁed from cDNA of Min6
cells (gift from C. Wollheim, Geneva), and the Zeb1 3′UTR harboring miR-200 site
mutations was PCR-ampliﬁed from a RT2_Zeb1200M tumor-derived cell line
(primers listed in Supplementary Table 1) and cloned into pmirGLO. Zeb1 3′UTRs
with either miR-200c or miR-141 sites mutated were de novo synthesized (Gen-
script) and cloned into pmirGLO. Min6 cells were cultured in 96-well plates and
transfected with 400 ng of pmirGLO reporters. For luciferase experiments invol-
ving adenoviral overexpression (MOI 50) of miR-141~200c, miR-141, or miR-200c,
cells were infected upon media change 6 h post-transfection with the pmirGLO
plasmids. Cells were harvested and assayed 48 h after transfection using the Dual-
Luciferase Reporter Assay System (Promega). Results were normalized to the
Renilla luciferase control contained in pmirGLO and expressed relative to ad-Ctrl-
treated cells transfected with the reporter containing the WT Zeb1 3′UTR.
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miRNA and gene-expression analysis. RNA was extracted using TRI Reagent
(Sigma-Aldrich). miRNA expression analysis was performed using TaqMan
MicroRNA Assays (ThermoFisher). For gene-expression analysis, RNA was reverse
transcribed using the High Capacity cDNA reverse transcription kit (Thermo-
Fisher), and qPCR was conducted using the gene-speciﬁc primers listed in Sup-
plementary Table 1 and 2x KAPA SYBR FAST qPCR MM (Kapa Biosystems).
Relative expression values were calculated using the ddCT and Pfafﬂ methods
employing snoRNA202 for miRNA or mouse 36b4 (Rplp0) for gene-expression
normalization. For absolute quantiﬁcation of miRNA levels and the ability to
compare between different TaqMan miRNA probes, synthetic miRNAs (Micro-
synth) comprising the mature miRNA sequence (mmu-miR-200c-3p, 5′-
UAAUACUGCCGGGUAAUGAUGGA-3′; mmu-miR-141-3p, 5′-UAACACU-
GUCUGGUAAAGAUGG-3′) were serially diluted and spiked into RT2_DKO
RNA (no endogenous miR-200 expression) and used to build a standard curve.
siRNA knockdown. For the siRNA screen, a list of regulated miR-200c target genes
was generated by selecting predicted miR-200c target genes (Targetscan v6.2) that
were signiﬁcantly (FDR ≤ 0.05) and minimum 1.3-fold upregulated in an initial set
of RNA sequencing samples of 6-week-islets. RT2_DKO cells were seeded in 24-
well plates and transfected the next day with 50 nM siRNA (pools of four siRNAs,
Dharmacon, Supplementary Table 1) using RNAiMax (ThermoFisher). Cells were
harvested 48 h later, and RNA was extracted for subsequent RT-qPCR. Data were
normalized to results from cells transfected with pooled siRNAs to a scrambled
control. To further conﬁrm our results using Zeb1 siRNAs and discount the
possibility of off-target effects, we performed deconvolution of our siRNA pools by
transfecting cells with individual siRNAs and conﬁrmed consistent regulation of
Cdh1, Epcam, and Ocln upon Zeb1 knockdown.
To conﬁrm the identity of the correct ZEB1 band in immunoblots with
RT2_DKO cells as well as the speciﬁcity of knockdown of Zeb1 rather than Zeb2
(Supplementary Figure 9b), RT2_DKO cells were transfected with 50 nM siZeb1,
siZeb2, or a combination of both, and harvested 72 h later.
RNA sequencing. RNA was extracted from islets isolated from 6-week-old mice
using the Picopure RNA Isolation kit (ThermoFisher), and from cell lines using
TRI-Reagent (Sigma-Aldrich) followed by RNeasy column puriﬁcation (Qiagen),
with on-column DNase (Qiagen) digestion for all samples. Library preparation
using the TruSeq Stranded mRNA Library Prep Kit (Illumina) and sequencing was
performed at the Functional Genomics Center Zurich (FGCZ) on a HiSeq 4000
platform.
Statistical analysis. Numerical values are reported as average ± s.d. unless stated
otherwise. No statistical method was used to predetermine sample size; sample size
was instead based on preliminary data and previous publications as well as
observed effect sizes. No randomization of animals was performed, but animals
were age-matched, and littermates were used whenever possible. Statistical analysis
was performed using GraphPad Prism 7.0. If not mentioned otherwise in the ﬁgure
legend, statistical signiﬁcance (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, ****P ≤ 0.001)
was determined by unpaired two-tailed t test, or one-way Anova with relevant
post-hoc tests (Dunnett if not speciﬁed otherwise). P values for pathway enrich-
ment were determined by Ingenuity software (Qiagen).
Bioinformatic analysis of sequencing data. Detailed information on bioinfor-
matics analysis of sequencing data can be found in the Supplementary Methods.
Data availability
Sequencing data are available in ArrayExpress under accession number E-MTAB-
6717.
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